ABBV-3373-A NOVEL IMMUNOLOGY ANTIBODY DRUG CONJUGATE: RESULTS FROM A FIRST-IN-HUMAN SINGLE ASCENDING DOSE STUDY IN HEALTHY SUBJECTS TO SUPPORT DOSE SELECTION FOR THE PROOF-OF-CONCEPT STUDY IN RHEUMATOID ARTHRITIS PATIENTS.

被引：0
|
作者：
D'Cunha, R. [1 ]
Kupper, H. [2 ]
Arikan, D. [1 ]
Zhao, W. [1 ]
Ruzek, M. [3 ]
Kang, B. [3 ]
Doelger, E. [2 ]
Carter, D. [1 ]
Pang, Y. [1 ]
机构：
[1] AbbVie, N Chicago, IL 60064 USA
[2] AbbVie Deutschland, Ludwigshafen, Germany
[3] AbbVie Biores Ctr, Worcester, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIV-058
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 25 条
  • [11] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY: RESULTS FROM THE FIRST-IN-HUMAN SINGLE DOSE ESCALATION STUDY IN HEALTHY VOLUNTEERS
    Khlyabova, P.
    Eremeeva, A.
    Lutckii, A.
    Dokukina, E.
    Chemyaeva, E.
    Ivanov, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 884 - 885
  • [12] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
    Bendell, Johanna
    Blumenschein, George
    Zinner, Ralph
    Hong, David
    Jones, Suzanne
    Infante, Jeffrey
    Burris, Howard
    Rajagopalan, Prabhu
    Kornacker, Martin
    Henderson, David
    Kelly, Andrea
    Hassan, Raffit
    CANCER RESEARCH, 2013, 73 (08)
  • [13] Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
    Smolen, Josef S.
    Weinblatt, Michael E.
    Sheng, Shihong
    Zhuang, Yanli
    Hsu, Benjamin
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) : 1616 - 1625
  • [14] Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
    Konecny, Gottfried E.
    Hendrickson, Andrea Elisabeth Wahner
    Winterhoff, Boris
    Chander, Cinthiya
    Bilic, Sanela
    Davenport, Simon
    Chung, Adrine
    Miller, Lei-Lani
    Press, Michael F.
    Letrent, Stephen P.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] First-in-human results from a phase 1 single- and multiple-ascending dose study in healthy participants assessing the safety, pharmacokinetics, and pharmacodynamics of the interleukin-17A inhibitor JNJ-81241459
    Ling, I.
    Leung, M.
    Piantone, A.
    Sinha, V.
    Song, D.
    Scott, B.
    Pryor, M.
    Verbruggen, K.
    La, D.
    Tikhonov, I.
    Ceulemans, K.
    Nischal, S.
    Polak, M.
    Eidam, P.
    Goldberg, S.
    Rao, R.
    Yang, Y-W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S375 - S375
  • [16] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Hsu, B.
    Sheng, S.
    Smolen, J. S.
    Weinblatt, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
  • [18] Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors
    Bashir, Babar
    Wang, Judy S.
    Falchook, Gerald
    Fontana, Elisa
    Arkenau, Hendrik-Tobias
    Carter, Louise
    Galot, Rachel
    Basu, Bristi
    Greystoke, Alastair
    Subbiah, Vivek
    Richardson, Debra L.
    Orr, Hanna
    Bennett, Gavin
    Sharma, Rajiv
    Xu, Hongmei
    Paganoni, Paola
    Xu, Cong
    Campbell, Carly
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [19] Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy.
    Hsu, Benjamin
    Sheng, Shihong
    Smolen, Josef
    Weinblatt, Michael
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1034 - S1034
  • [20] INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Cortes, J.
    DeAngelo, D.
    Wang, E.
    Arana-Yi, C.
    Zweidler-McKay, P.
    Munteanu, M.
    Andreu-Vieyra, C.
    Erba, H.
    Blum, W.
    Traer, E.
    HAEMATOLOGICA, 2017, 102 : 217 - 218
123